191 related articles for article (PubMed ID: 12771309)
21. Biochemical and cellular effects of direct maxacalcitol injection into parathyroid gland in uremic rats.
Shiizaki K; Negi S; Hatamura I; Sakaguchi T; Saji F; Kunimoto K; Mizobuchi M; Imazeki I; Ooshima A; Akizawa T
J Am Soc Nephrol; 2005 Jan; 16(1):97-108. PubMed ID: 15574509
[TBL] [Abstract][Full Text] [Related]
22. Calcimimetic compound upregulates decreased calcium-sensing receptor expression level in parathyroid glands of rats with chronic renal insufficiency.
Mizobuchi M; Hatamura I; Ogata H; Saji F; Uda S; Shiizaki K; Sakaguchi T; Negi S; Kinugasa E; Koshikawa S; Akizawa T
J Am Soc Nephrol; 2004 Oct; 15(10):2579-87. PubMed ID: 15466262
[TBL] [Abstract][Full Text] [Related]
23. [Pharmacological and clinical trial data on a novel phosphate-binding polymer (sevelamer hydrochloride), a medicine for hyperphosphatemia in hemodialysis patients].
Nagano N; Fukushima N
Nihon Yakurigaku Zasshi; 2003 Nov; 122(5):443-53. PubMed ID: 14569164
[TBL] [Abstract][Full Text] [Related]
24. Phosphorus accelerates the development of parathyroid hyperplasia and secondary hyperparathyroidism in rats with renal failure.
Denda M; Finch J; Slatopolsky E
Am J Kidney Dis; 1996 Oct; 28(4):596-602. PubMed ID: 8840952
[TBL] [Abstract][Full Text] [Related]
25. Combination therapy with sevelamer hydrochloride and calcium carbonate in Japanese patients with long-term hemodialysis: alternative approach for optimal mineral management.
Ogata H; Koiwa F; Shishido K; Kinugasa E
Ther Apher Dial; 2005 Feb; 9(1):11-5. PubMed ID: 15828900
[TBL] [Abstract][Full Text] [Related]
26. The impact of improved phosphorus control: use of sevelamer hydrochloride in patients with chronic renal failure.
Amin N
Nephrol Dial Transplant; 2002 Feb; 17(2):340-5. PubMed ID: 11812903
[TBL] [Abstract][Full Text] [Related]
27. Two Years of Cinacalcet Hydrochloride Treatment Decreased Parathyroid Gland Volume and Serum Parathyroid Hormone Level in Hemodialysis Patients With Advanced Secondary Hyperparathyroidism.
Yamada S; Tokumoto M; Taniguchi M; Toyonaga J; Suehiro T; Eriguchi R; Fujimi S; Ooboshi H; Kitazono T; Tsuruya K
Ther Apher Dial; 2015 Aug; 19(4):367-77. PubMed ID: 25851690
[TBL] [Abstract][Full Text] [Related]
28. Direct maxacalcitol injection into hyperplastic parathyroids improves skeletal changes in secondary hyperparathyroidism.
Shiizaki K; Hatamura I; Negi S; Sakaguchi T; Saji F; Kunimoto K; Okamoto M; Imazeki I; Muragaki Y; Akizawa T
Kidney Int; 2006 Aug; 70(3):486-95. PubMed ID: 16788697
[TBL] [Abstract][Full Text] [Related]
29. Meta-analysis of the effect of sevelamer on phosphorus, calcium, PTH, and serum lipids in dialysis patients.
Burke SK; Dillon MA; Hemken DE; Rezabek MS; Balwit JM
Adv Ren Replace Ther; 2003 Apr; 10(2):133-45. PubMed ID: 12879374
[TBL] [Abstract][Full Text] [Related]
30. Sevelamer hydrochloride with or without alphacalcidol or higher dialysate calcium vs calcium carbonate in dialysis patients: an open-label, randomized study.
Sadek T; Mazouz H; Bahloul H; Oprisiu R; El Esper N; El Esper I; Boitte F; Brazier M; Moriniere P; Fournier A
Nephrol Dial Transplant; 2003 Mar; 18(3):582-8. PubMed ID: 12584283
[TBL] [Abstract][Full Text] [Related]
31. Effect of sevelamer hydrochloride on bone in experimental uremic rats.
Kuwahara M; Inoshita S; Terada Y; Sasaki S
Ther Apher Dial; 2009 Feb; 13(1):42-8. PubMed ID: 19379169
[TBL] [Abstract][Full Text] [Related]
32. A new analog of 1,25-(OH)2D3, 19-NOR-1,25-(OH)2D2, suppresses serum PTH and parathyroid gland growth in uremic rats without elevation of intestinal vitamin D receptor content.
Takahashi F; Finch JL; Denda M; Dusso AS; Brown AJ; Slatopolsky E
Am J Kidney Dis; 1997 Jul; 30(1):105-12. PubMed ID: 9214408
[TBL] [Abstract][Full Text] [Related]
33. Treatment of hyperphosphatemia with sevelamer hydrochloride in hemodialysis patients: a comparison with calcium acetate.
Hervás JG; Prados D; Cerezo S
Kidney Int Suppl; 2003 Jun; (85):S69-72. PubMed ID: 12753270
[TBL] [Abstract][Full Text] [Related]
34. Cyclooxygenase 2 promotes parathyroid hyperplasia in ESRD.
Zhang Q; Qiu J; Li H; Lu Y; Wang X; Yang J; Wang S; Zhang L; Gu Y; Hao CM; Chen J
J Am Soc Nephrol; 2011 Apr; 22(4):664-72. PubMed ID: 21335517
[TBL] [Abstract][Full Text] [Related]
35. Direct injection of calcitriol or its analog improves abnormal gene expression in the hyperplastic parathyroid gland in uremia.
Shiizaki K; Fukagawa M; Yuan Q; Hatamura I; Nii-Kono T; Saji F; Shigematsu T; Akizawa T
Am J Nephrol; 2008; 28(1):59-66. PubMed ID: 17901691
[TBL] [Abstract][Full Text] [Related]
36. Cinacalcet HCl attenuates parathyroid hyperplasia in a rat model of secondary hyperparathyroidism.
Colloton M; Shatzen E; Miller G; Stehman-Breen C; Wada M; Lacey D; Martin D
Kidney Int; 2005 Feb; 67(2):467-76. PubMed ID: 15673294
[TBL] [Abstract][Full Text] [Related]
37. Sevelamer hydrochloride: an effective phosphate binder in dialyzed children.
Mahdavi H; Kuizon BD; Gales B; Wang HJ; Elashoff RM; Salusky IB
Pediatr Nephrol; 2003 Dec; 18(12):1260-4. PubMed ID: 14586677
[TBL] [Abstract][Full Text] [Related]
38. Zinc nutritional status modifies renal osteodystrophy in uremic rats.
Kimmel PL; Langman CB; Bognar B; Faugere MC; Chawla LS; Watkins DW; Malluche HH
Clin Nephrol; 2001 Dec; 56(6):445-58. PubMed ID: 11770796
[TBL] [Abstract][Full Text] [Related]
39. [Sevelamer hydrochloride prevents ectopic calcification of blood vessels].
Fukushima N; Nagano N
Clin Calcium; 2004 Jun; 14(6):116-22. PubMed ID: 15577065
[TBL] [Abstract][Full Text] [Related]
40. Decrease in thoracic vertebral bone attenuation with calcium-based phosphate binders in hemodialysis.
Raggi P; James G; Burke SK; Bommer J; Chasan-Taber S; Holzer H; Braun J; Chertow GM
J Bone Miner Res; 2005 May; 20(5):764-72. PubMed ID: 15824849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
